Gp130 on macrophages/granulocytes modulates inflammation during experimental tuberculosis

European Journal of Cell Biology

Volumn 90, Issue 6-7, 2011, Pages 505-514

  Sodenkamp, Jan ^a   Behrends, Jochen ^a   Förster, Irmgard ^b   Müller, Werner ^c   Ehlers, Stefan ^a,d,e   Hölscher, Christoph ^a,e  

^a RESEARCH CENTER BORSTEL   (Germany)

^b HEINRICH HEINE UNIVERSITY   (Germany)

^c UNIVERSITY OF MANCHESTER   (United Kingdom)

^d UNIVERSITY OF KIEL   (Germany)

^e Christian Albrecht University ^*  (Germany)

Author keywords

Bacterial infection; Cytokines; Macrophages monocytes; Rodent; T cells

Indexed keywords

GELATINASE B; GLYCOPROTEIN GP 130; INDUCIBLE NITRIC OXIDE SYNTHASE; INTERLEUKIN 27;

ARTICLE; BACTERIAL LOAD; CHRONIC INFLAMMATION; CYTOKINE RELEASE; GRANULOCYTE; HELPER CELL; HUMAN; IMMUNE RESPONSE; IMMUNOREGULATION; MACROPHAGE; MOUSE; NEUTROPHIL; NONHUMAN; PATHOLOGY; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; TH17 CELL; TUBERCULOSIS;

ANIMALS; CYTOKINE RECEPTOR GP130; DISEASE MODELS, ANIMAL; GRANULOCYTES; HUMANS; INFLAMMATION; MACROPHAGES; MICE; TUBERCULOSIS;

BACTERIA (MICROORGANISMS); MUS; RODENTIA;

EID: 79955483507     PISSN: 01719335     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejcb.2010.10.010     Document Type: Article

References (50)

1. Aderka D., Le J.M., Vilcek J. IL-6 inhibits lipopolysaccharide-induced tumor necrosis factor production in cultured human monocytes, U937 cells, and in mice. J Immunol 1989, 143:3517-3523.
2. Betz U.A., Bloch W., van den Broek M., Yoshida K., Taga T., Kishimoto T., Addicks K., Rajewsky K., Muller W. Postnatally induced inactivation of gp130 in mice results in neurological, cardiac, hematopoietic, immunological, hepatic, and pulmonary defects. J Exp Med 1998, 188:1955-1965.
3. Clausen B.E., Burkhardt C., Reith W., Renkawitz R., Forster I. Conditional gene targeting in macrophages and granulocytes using LysMcre mice. Transgenic Res 1999, 8:265-277.
4. Cooper A.M., Magram J., Ferrante J., Orme I.M. Interleukin 12 (IL-12) is crucial to the development of protective immunity in mice intravenously infected with Mycobacterium tuberculosis. J Exp Med 1997, 186:39-45.
5. Herbert D.R., Hölscher C., Mohrs M., Arendse B., Schwegmann A., Radwanska M., Leeto M., Kirsch R., Hall P., Mossmann H., Claussen B., Förster I., Brombacher F. Alternative macrophage activation is essential for survival during schistosomiasis and downmodulates T helper 1 responses and immunopathology. Immunity 2004, 20:623-635.
6. Hölscher C. The power of combinatorial immunology: IL-12 and IL-12-related dimeric cytokines in infectious diseases. Med Microbiol Immunol 2004, 193:1-17.
7. Hölscher C. Targeting IL-23 in autoimmunity. Curr Opin Investig Drugs 2005, 6:489-495.
8. Hölscher C., Atkinson R.A., Arendse B., Brown N., Myburgh E., Alber G., Brombacher F. A protective and agonistic function of IL-12p40 in mycobacterial infection. J Immunol 2001, 167:6957-6966.
9. Hölscher C., Hölscher A., Rückerl D., Yoshimoto T., Yoshida H., Mak T., Saris C., Ehlers S. The IL-27 receptor chain WSX-1 differentially regulates antibacterial immunity and survival during experimental tuberculosis. J Immunol 2005, 174:3534-3544.
10. Hölscher C., Köhler G., Müller U., Mossmann H., Schaub G.A., Brombacher F. Defective nitric oxide effector functions lead to extreme susceptibility of Trypanosoma cruzi-infected mice deficient in gamma interferon receptor or inducible nitric oxide synthase. Infect Immun 1998, 66:1208-1215.
11. Ivanov I.I., McKenzie B.S., Zhou L., Tadokoro C.E., Lepelley A., Lafaille J.J., Cua D.J., Littman D.R. The orphan nuclear receptor RORgammat directs the differentiation program of proinflammatory IL-17+ T helper cells. Cell 2006, 126:1121-1133.
12. Keane J., Gershon S., Wise R.P., Mirabile-Levens E., Kasznica J., Schwieterman W.D., Siegel J.N., Braun M.M. Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent. N Engl J Med 2001, 345:1098-1104.
13. Keller C., Hoffmann R., Lang R., Brandau S., Hermann C., Ehlers S. Genetically determined susceptibility to tuberculosis in mice causally involves accelerated and enhanced recruitment of granulocytes. Infect Immun 2006, 74:4295-4309.
14. Khader S.A., Bell G.K., Pearl J.E., Fountain J.J., Rangel-Moreno J., Cilley G.E., Shen F., Eaton S.M., Gaffen S.L., Swain S.L., Locksley R.M., Haynes L., Randall T.D., Cooper A.M. IL-23 and IL-17 in the establishment of protective pulmonary CD4+ T cell responses after vaccination and during Mycobacterium tuberculosis challenge. Nat Immunol 2007, 8:369-377.
15. Khader S.A., Pearl J.E., Sakamoto K., Gilmartin L., Bell G.K., Jelley-Gibbs D.M., Ghilardi N., deSauvage F., Cooper A.M. IL-23 compensates for the absence of IL-12p70 and is essential for the IL-17 response during tuberculosis but is dispensable for protection and antigen-specific IFN-gamma responses if IL-12p70 is available. J Immunol 2005, 175:788-795.
16. Koenders M.I., Kolls J.K., Oppers-Walgreen B., van den Bersselaar L., Joosten L.A., Schurr J.R., Schwarzenberger P., van den Berg W.B., Lubberts E. Interleukin-17 receptor deficiency results in impaired synovial expression of interleukin-1 and matrix metalloproteinases 3, 9, and 13 and prevents cartilage destruction during chronic reactivated streptococcal cell wall-induced arthritis. Arthritis Rheum 2005, 52:3239-3247.
17. Ladel C.H., Blum C., Dreher A., Reifenberg K., Kopf M., Kaufmann S.H. Lethal tuberculosis in interleukin-6-deficient mutant mice. Infect Immun 1997, 65:4843-4849.
18. Langrish C.L., Chen Y., Blumenschein W.M., Mattson J., Basham B., Sedgwick J.D., McClanahan T., Kastelein R.A., Cua D.J. IL-23 drives a pathogenic T cell population that induces autoimmune inflammation. J Exp Med 2005, 201:233-240.
19. Leal I.S., Smedegard B., Andersen P., Appelberg R. Interleukin-6 and interleukin-12 participate in induction of a type 1 protective T-cell response during vaccination with a tuberculosis subunit vaccine. Infect Immun 1999, 67:5747-5754.
20. Leng S.X., Elias J.A. Interleukin-11 inhibits macrophage interleukin-12 production. J Immunol 1997, 159:2161-2168.
21. Lyadova I.V., Tsiganov E.N., Kapina M.A., Shepelkova G.S., Sosunov V.V., Radaeva T.V., Majorov K.B., Shmitova N.S., van den Ham H.J., Ganusov V.V., De Boer R.J., Racine R., Winslow G.M. In mice, tuberculosis progression is associated with intensive inflammatory response and the accumulation of Gr-1 cells in the lungs. PLoS One 2010, 5:e10469.
22. MacMicking J.D., Nathan C., Hom G., Chartrain N., Fletcher D.S., Trumbauer M., Stevens K., Xie Q.W., Sokol K., Hutchinson N., et al. Altered responses to bacterial infection and endotoxic shock in mice lacking inducible nitric oxide synthase. Cell 1995, 81:641-650.
23. MacMicking J.D., Taylor G.A., McKinney J.D. Immune control of tuberculosis by IFN-gamma-inducible LRG-47. Science 2003, 302:654-659.
24. Maniar J.K., Kamath R.R., Mandalia S., Shah K., Maniar A. HIV and tuberculosis: partners in crime. Indian J Dermatol Venereol Leprol 2006, 72:276-282.
25. Mohan A.K., Cote T.R., Block J.A., Manadan A.M., Siegel J.N., Braun M.M. Tuberculosis following the use of etanercept, a tumor necrosis factor inhibitor. Clin Infect Dis 2004, 39:295-299.
26. Murphy C.A., Langrish C.L., Chen Y., Blumenschein W., McClanahan T., Kastelein R.A., Sedgwick J.D., Cua D.J. Divergent pro- and antiinflammatory roles for IL-23 and IL-12 in joint autoimmune inflammation. J Exp Med 2003, 198:1951-1957.
27. North R.J., Jung Y.J. Immunity to tuberculosis. Annu Rev Immunol 2004, 22:599-623.
28. Okamoto Yoshida Y., Umemura M., Yahagi A., O'Brien R.L., Ikuta K., Kishihara K., Hara H., Nakae S., Iwakura Y., Matsuzaki G. Essential role of IL-17A in the formation of a mycobacterial infection-induced granuloma in the lung. J Immunol 2010, 184:4414-4422.
29. Pearl J.E., Khader S.A., Solache A., Gilmartin L., Ghilardi N., deSauvage F., Cooper A.M. IL-27 signaling compromises control of bacterial growth in mycobacteria-infected mice. J Immunol 2004, 173:7490-7496.
30. Pettersson T., Welin M.G., Weber T.H. In vitro production of leucocyte migration inhibitory factor by lymphocytes in exudative pleural effusions. J Clin Lab Immunol 1982, 8:107-111.
31. Prause O., Bozinovski S., Anderson G.P., Linden A. Increased matrix metalloproteinase-9 concentration and activity after stimulation with interleukin-17 in mouse airways. Thorax 2004, 59:313-317.
32. Price N.M., Farrar J., Tran T.T., Nguyen T.H., Tran T.H., Friedland J.S. Identification of a matrix-degrading phenotype in human tuberculosis in vitro and in vivo. J Immunol 2001, 166:4223-4230.
33. Reiling N., Holscher C., Fehrenbach A., Kroger S., Kirschning C.J., Goyert S., Ehlers S. Cutting edge: Toll-like receptor (TLR)2- and TLR4-mediated pathogen recognition in resistance to airborne infection with Mycobacterium tuberculosis. J Immunol 2002, 169:3480-3484.
34. Rose-John S., Schooltink H. Cytokines are a therapeutic target for the prevention of inflammation-induced cancers. Recent Results Cancer Res 2007, 174:57-66.
35. Rose-John S., Waetzig G.H., Scheller J., Grotzinger J., Seegert D. The IL-6/sIL-6R complex as a novel target for therapeutic approaches. Expert Opin Ther Targets 2007, 11:613-624.
36. Rückerl D., Hessmann M., Yoshimoto T., Ehlers S., Hölscher C. Alternatively activated macrophages express the IL-27 receptor alpha chain WSX-1. Immunobiology 2006, 211:427-436.
37. Sander L.E., Obermeier F., Dierssen U., Kroy D.C., Singh A.K., Seidler U., Streetz K.L., Lutz H.H., Muller W., Tacke F., Trautwein C. Gp130 signaling promotes development of acute experimental colitis by facilitating early neutrophil/macrophage recruitment and activation. J Immunol 2008, 181:3586-3594.
38. Saunders B.M., Frank A.A., Orme I.M., Cooper A.M. Interleukin-6 induces early gamma interferon production in the infected lung but is not required for generation of specific immunity to Mycobacterium tuberculosis infection. Infect Immun 2000, 68:3322-3326.
39. Stumhofer J.S., Laurence A., Wilson E.H., Huang E., Tato C.M., Johnson L.M., Villarino A.V., Huang Q., Yoshimura A., Sehy D., Saris C.J., O'Shea J.J., Hennighausen L., Ernst M., Hunter C.A. Interleukin 27 negatively regulates the development of interleukin 17-producing T helper cells during chronic inflammation of the central nervous system. Nat Immunol 2006, 7:937-945.
40. Taga T., Kishimoto T. Gp130 and the interleukin-6 family of cytokines. Annu Rev Immunol 1997, 15:797-819.
41. Takeda K., Clausen B.E., Kaisho T., Tsujimura T., Terada N., Forster I., Akira S. Enhanced Th1 activity and development of chronic enterocolitis in mice devoid of Stat3 in macrophages and neutrophils. Immunity 1999, 10:39-49.
42. Tufariello J.M., Chan J., Flynn J.L. Latent tuberculosis: mechanisms of host and bacillus that contribute to persistent infection. Lancet Infect Dis 2003, 3:578-590.
43. Umemura M., Yahagi A., Hamada S., Begum M.D., Watanabe H., Kawakami K., Suda T., Sudo K., Nakae S., Iwakura Y., Matsuzaki G. IL-17-mediated regulation of innate and acquired immune response against pulmonary Mycobacterium bovis bacille Calmette-Guerin infection. J Immunol 2007, 178:3786-3796.
44. Villarino A., Hibbert L., Lieberman L., Wilson E., Mak T., Yoshida H., Kastelein R.A., Saris C., Hunter C.A. The IL-27R (WSX-1) is required to suppress T cell hyperactivity during infection. Immunity 2003, 19:645-655.
45. Villarino A.V., Huang E., Hunter C.A. Understanding the pro- and anti-inflammatory properties of IL-27. J Immunol 2004, 173:715-720.
46. Wakeham J., Wang J., Magram J., Croitoru K., Harkness R., Dunn P., Zganiacz A., Xing Z. Lack of both types 1 and 2 cytokines, tissue inflammatory responses, and immune protection during pulmonary infection by Mycobacterium bovis bacille Calmette-Guerin in IL-12-deficient mice. J Immunol 1998, 160:6101-6111.
47. Werninghaus K., Babiak A., Gross O., Holscher C., Dietrich H., Agger E.M., Mages J., Mocsai A., Schoenen H., Finger K., Nimmerjahn F., Brown G.D., Kirschning C., Heit A., Andersen P., Wagner H., Ruland J., Lang R. Adjuvanticity of a synthetic cord factor analogue for subunit Mycobacterium tuberculosis vaccination requires FcRgamma-Syk-Card9-dependent innate immune activation. J Exp Med 2009, 206:89-97.
48. WHO Global Tuberculosis Control - Surveillance, Planning, Financing 2008, WHO, Geneva, Switzerland.
49. Wirtz S., Tubbe I., Galle P.R., Schild H.J., Birkenbach M., Blumberg R.S., Neurath M.F. Protection from lethal septic peritonitis by neutralizing the biological function of interleukin 27. J Exp Med 2006, 203:1875-1881.
50. Ye P., Rodriguez F.H., Kanaly S., Stocking K.L., Schurr J., Schwarzenberger P., Oliver P., Huang W., Zhang P., Zhang J., Shellito J.E., Bagby G.J., Nelson S., Charrier K., Peschon J.J., Kolls J.K. Requirement of interleukin 17 receptor signaling for lung CXC chemokine and granulocyte colony-stimulating factor expression, neutrophil recruitment, and host defense. J Exp Med 2001, 194:519-527.